title: Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers.
abstract: BACKGROUND
  The authors compared the types of treatments prostate cancer patients received from county hospitals and private providers as part of a statewide public assistance program.
  
  
  METHODS
  This was a cohort study of 559 men enrolled in a state-funded program for low-income patients known as Improving Access, Counseling, and Treatment for Californians With Prostate Cancer (IMPACT). Multinomial regression was used to compare types of treatments patients received from different providers.
  
  
  RESULTS
  Between 2001 and 2006, 315 (56%) participants received treatment from county hospitals and 244 (44%) from private providers. There were no significant between-group differences with respect to age (P = .22), enrollment year (P = .49), Charlson comorbidity index (P = .47), Gleason sum (P = .33), clinical T stage (P = .36), prostate-specific antigen (P = .39), or D'Amico risk criteria (P = .45). Participants treated by private providers were more likely than those treated in county hospitals to be white (35% vs 10%, P < .01) and less likely to undergo surgery (29% vs 54%, P < .01). Multinomial regression analyses showed that participants treated by private providers were nearly 2(1/2) times more likely than those treated by public providers to receive radiotherapy (odds ratio [OR], 2.36; 95% confidence interval [CI], 1.37-4.07) and >4(1/2) times more likely to receive primary androgen deprivation (OR, 4.71; 95% CI, 2.15-10.36) than surgery.
  
  
  CONCLUSIONS
  In this economically disadvantaged cohort, prostate cancer treatments differed significantly between county hospitals and private providers. These data reveal substantial variations in treatment patterns between different types of healthcare institutions that-given the implications for health policy and quality of care-merit further scrutiny.
authors.affiliation: Moores Comprehensive Cancer Center, University of California, La Jolla, CA, USA. leparker@ucsd.edu
authors.forename: J Kellogg
authors.initials: JK
authors.lastname: Parsons
authors.forename: Lorna
authors.initials: L
authors.lastname: Kwan
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Connor
authors.forename: David C
authors.initials: DC
authors.lastname: Miller
authors.forename: Mark S
authors.initials: MS
authors.lastname: Litwin
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D006766:Hospitals, County; D016304:Hospitals, Private; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000191:economics / Q000532:radiotherapy* / Q000601:surgery*; D011787:Quality of Health Care / Q000191:economics; D035862:Vulnerable Populations
chemical_list: D000726:Androgen Antagonists